Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akiko Watanabe

Showing results (31-40 of 220) with videos related to

Pageof 22
Sort By:
Genome Research|March 5, 2002
Identification of multiple genetic loci linked to the propensity for "behavioral despair" in miceTakeo Yoshikawa, Akiko Watanabe, Yuichi Ishitsuka, et al.
Drug Metabolism and Pharmacokinetics|May 15, 2007
Effect of ion suppression on judgment of enzyme inhibition and avoidance of error by utilizing a stable isotope-labeled probe substrate: example of CYP3A4 inhibition with [13C4,15N] labeled midazolam as a substrateKoichi Nakamura, Akiko Watanabe, Noriko Okudaira, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|December 16, 2006
[Non-convulsive status epilepticus due to discontinuation of taking a benzodiazepine]Nozomu Matsuda, Kouichiro Nakamura, Akiko Watanabe, et al.
Frontiers in Aging Neuroscience|May 28, 2020
Clinical and Genetic Aspects of CADASILToshiki Mizuno, Ikuko Mizuta, Akiko Watanabe-Hosomi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expressionKazu Kikuchi, Hirotake Kasai, Akiko Watanabe, et al.
Experimental Neurology|November 15, 2011
Transendocytosis is impaired in CADASIL-mutant NOTCH3Akiko Watanabe-Hosomi, Yoshihisa Watanabe, Masaki Tanaka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 30, 2007
Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery processAkiko Watanabe, Koichi Nakamura, Noriko Okudaira, et al.
Scientific Reports|May 12, 2018
Cavitation-threshold Determination and Rheological-parameters Estimation of Albumin-stabilized NanobubblesMaxime Lafond, Akiko Watanabe, Shin Yoshizawa, et al.
Plant Physiology|August 28, 2007
Posttranscriptional regulation of high-affinity sulfate transporters in Arabidopsis by sulfur nutritionNaoko Yoshimoto, Eri Inoue, Akiko Watanabe-Takahashi, et al.
European Journal of Clinical Pharmacology|August 20, 2021
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairmentAkiko Watanabe, Tomoko Ishizuka, Makiko Yamada, et al.
Pageof 22

Showing results (31-40 of 220) with videos related to

Sort By:
Pageof 22
Genome Research|March 5, 2002
Identification of multiple genetic loci linked to the propensity for "behavioral despair" in miceTakeo Yoshikawa, Akiko Watanabe, Yuichi Ishitsuka, et al.
Drug Metabolism and Pharmacokinetics|May 15, 2007
Effect of ion suppression on judgment of enzyme inhibition and avoidance of error by utilizing a stable isotope-labeled probe substrate: example of CYP3A4 inhibition with [13C4,15N] labeled midazolam as a substrateKoichi Nakamura, Akiko Watanabe, Noriko Okudaira, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|December 16, 2006
[Non-convulsive status epilepticus due to discontinuation of taking a benzodiazepine]Nozomu Matsuda, Kouichiro Nakamura, Akiko Watanabe, et al.
Frontiers in Aging Neuroscience|May 28, 2020
Clinical and Genetic Aspects of CADASILToshiki Mizuno, Ikuko Mizuta, Akiko Watanabe-Hosomi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expressionKazu Kikuchi, Hirotake Kasai, Akiko Watanabe, et al.
Experimental Neurology|November 15, 2011
Transendocytosis is impaired in CADASIL-mutant NOTCH3Akiko Watanabe-Hosomi, Yoshihisa Watanabe, Masaki Tanaka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 30, 2007
Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery processAkiko Watanabe, Koichi Nakamura, Noriko Okudaira, et al.
Scientific Reports|May 12, 2018
Cavitation-threshold Determination and Rheological-parameters Estimation of Albumin-stabilized NanobubblesMaxime Lafond, Akiko Watanabe, Shin Yoshizawa, et al.
Plant Physiology|August 28, 2007
Posttranscriptional regulation of high-affinity sulfate transporters in Arabidopsis by sulfur nutritionNaoko Yoshimoto, Eri Inoue, Akiko Watanabe-Takahashi, et al.
European Journal of Clinical Pharmacology|August 20, 2021
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairmentAkiko Watanabe, Tomoko Ishizuka, Makiko Yamada, et al.
Pageof 22